Phreesia (NYSE:PHR) CFO Balaji Gandhi Sells 3,829 Shares

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 3,829 shares of Phreesia stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $11.26, for a total transaction of $43,114.54. Following the sale, the chief financial officer owned 146,740 shares of the company’s stock, valued at $1,652,292.40. The trade was a 2.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Balaji Gandhi also recently made the following trade(s):

• On Friday, January 16th, Balaji Gandhi sold 4,687 shares of Phreesia stock. The stock was sold at an average price of $16.36, for a total value of $76,679.32.
• On Thursday, January 15th, Balaji Gandhi sold 975 shares of Phreesia stock. The shares were sold at an average price of $16.38, for a total value of $15,970.50.
• On Thursday, January 8th, Balaji Gandhi sold 8,009 shares of Phreesia stock. The stock was sold at an average price of $17.01, for a total value of $136,233.09.

Phreesia Price Performance

PHR opened at $10.96 on Friday. The company has a market capitalization of $660.54 million, a price-to-earnings ratio of -109.55 and a beta of 0.67. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01. Phreesia, Inc. has a 12-month low of $10.75 and a 12-month high of $32.76. The business’s fifty day simple moving average is $12.61 and its 200-day simple moving average is $17.83.

Analysts Set New Price Targets

Several research firms have recently commented on PHR. Robert W. Baird reduced their price target on shares of Phreesia from $31.00 to $25.00 and set an “outperform” rating for the company in a report on Wednesday, December 10th. Mizuho cut their price objective on shares of Phreesia from $22.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday, March 24th. Zacks Research downgraded shares of Phreesia from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Wall Street Zen cut Phreesia from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 8th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $35.00 price target on shares of Phreesia in a research report on Monday, December 8th. Seventeen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Phreesia currently has an average rating of “Moderate Buy” and a consensus target price of $28.65.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in PHR. Federated Hermes Inc. acquired a new stake in Phreesia in the third quarter worth about $32,000. Van ECK Associates Corp increased its holdings in shares of Phreesia by 78.7% during the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock valued at $42,000 after acquiring an additional 1,102 shares in the last quarter. Asset Management One Co. Ltd. purchased a new position in shares of Phreesia in the 3rd quarter valued at approximately $45,000. Rockefeller Capital Management L.P. raised its position in shares of Phreesia by 354.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company’s stock valued at $47,000 after purchasing an additional 2,149 shares during the last quarter. Finally, KBC Group NV boosted its stake in Phreesia by 83.4% in the 4th quarter. KBC Group NV now owns 3,449 shares of the company’s stock worth $58,000 after purchasing an additional 1,568 shares in the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.